HUTCHMED Limited - Expanded Access Programs

Sponsor Overview

Explore verified public information about HUTCHMED Limited's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.

Compliance Score

80 out of 100

Excellent

Evidence Library

Unique references curated across 1 content categories.

Clinical Trials

No trials referenced

ClinicalTrials.gov data sources power this status.

Last Verified

2025

Dataset refreshed continuously through Right2Hope ETL pipelines.

Official Sponsor Websitechi-med.com

Visit Site→

Expanded Access Intelligence

EAP Related Articles from Sponsor

Score contribution: 80 — 3 supporting sources.

Score 803 references

Featured Reference

US FDA Accepts Filing of HUTCHMED's NDA for Surufatinib for the ...Opens in new window

HUTCHMED has initiated an Expanded Access Protocol (EAP) in the U.S. to ensure patients with NET with limited therapeutic options have access to this treatment. Regulatory clearance of this protocol has been granted by the FDA and this program is open for site activation (clinicaltrials.gov identifier: NCT04814732).

HUTCHMED Announces TAZVERIK® Approved to be Used in ...Source

The approval of TAZVERIK® in the Hainan Pilot Zone allows patients to gain early access to this first-in-class EZH2 inhibitor in China, as part of our commitment to bringing innovative medicines to people in need.

HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib ...Source

Reagan-Udall Foundation Insights

Company

HUTCHMED Limited

Expanded Access Website

https://www.chi-med.com/innovation-platform/expanded-access/

Partner with Right2Hope

Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.

Talk to Our Team→Explore Programs